A Study of the Effect of Food on LY3537982 in Healthy Participants
- Registration Number
- NCT05824858
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 after meals and on an empty stomach. The study will also evaluate the safety and tolerability of LY3537982. Participants will stay in the research center during the study, which will last about one week, not including screening.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease
- Body mass index (BMI): 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
Exclusion Criteria
- Females who are lactating or of childbearing potential
- Clinically significant history of any drug sensitivity, drug allergy, or food allergy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description LY3537982 (High-Fat Meal) LY3537982 LY3537982 administered orally under fasting conditions in one study period and under fed conditions (i.e., a standard high-fat meal) in the other study period. LY3537982 (Low-Fat Meal) LY3537982 LY3537982 administered orally under fasting conditions in one study period and under fed conditions (i.e., a standard low-fat meal) in the other study period.
- Primary Outcome Measures
Name Time Method Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC[0-inf]) Day 1 and Day 4 of each study period PK: AUC(0-inf)
PK: Maximum Observed Concentration (Cmax) of LY3537982 Day 1 and Day 4 of each study period PK: Cmax of LY3537982
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
ICON
🇺🇸Salt Lake City, Utah, United States